AdaptDx is designed to be an easy to use macular degeneration diagnostic tool.
Investors contributing to MacuLogix’s Series A funding include Ben Franklin Technology Partners of Central and Northern Pennsylvania, Berwind Private Equity, Roche Venture Fund and Life Sciences Greenhouse of Central Pennsylvania.
More Articles on Ophthalmology:
Flaum Eye Institute Recruits Dr. Harold Ross
MCRHS Eye Care Welcomes Dr. Elizabeth Garland
AAO Survey Finds US Ophthalmologists Foresee Negative Consequences of Medicare Cuts
